Denali Therapeutics (DNLI) Institutional Ownership
13F filers reported holding 98.2% of Denali Therapeutics (DNLI) shares as of Jun 30, 2026, across 298 filers.
4 figures withheld by our checks. Each blank figure names its reason.
- Held by 13F filers
- 98.2%
- Jun 30, 2026
- 13F filers
- 298
- quarter ended Jun 30, 2026
- 13F value
- $4.0B
- 157.4M shares
Is the smart money (institutions and insiders) accumulating or distributing? One lagging input, not a buy signal.
| Date | Name | Role | Type | Shares | Price** | SEC filing |
|---|---|---|---|---|---|---|
| Sep 4, 2026 | Chin Peter Scott | Chief Medical Officer | Disposed · Open-market sale | 1,654 | $22.29 | ↗ |
| Sep 2, 2026 | Thornberry Nancy | director | Disposed · Open-market sale | 10,824 | $22.85 | ↗ |
| Sep 2, 2026 | Thornberry Nancy | director | Disposed · Open-market sale | 615 | $23.74 | ↗ |
| Sep 1, 2026 | Schuth Alexander O. | COFO and Secretary | Disposed · Open-market sale | 2,768 | $23.44 | ↗ |
| Aug 12, 2026 | Watts Ryan J. | President and CEO | Disposed · Gift | 32,220 | — | ↗ |
| Aug 11, 2026 | Schuth Alexander O. | COFO and Secretary | Disposed · Open-market sale | 2,857 | $25.07 | ↗ |
| Jun 3, 2026 | Van Hauwermeiren Timothy | director | Acquired · Grant / award | 6,408 | — | ↗ |
| Jun 3, 2026 | Van Hauwermeiren Timothy | director | Acquired · Grant / award | 19,226Stock Option (right to buy) | — | ↗ |
| Jun 3, 2026 | Thornberry Nancy | director | Acquired · Grant / award | 6,408 | — | ↗ |
| Jun 3, 2026 | Thornberry Nancy | director | Acquired · Grant / award | 19,226Stock Option (right to buy) | — | ↗ |
| Jun 3, 2026 | Cook Jennifer E. | director | Acquired · Grant / award | 6,408 | — | ↗ |
| Jun 3, 2026 | Cook Jennifer E. | director | Acquired · Grant / award | 19,226Stock Option (right to buy) | — | ↗ |
| Jun 3, 2026 | Krognes Steve E. | director | Acquired · Grant / award | 6,408 | — | ↗ |
| Jun 3, 2026 | Krognes Steve E. | director | Acquired · Grant / award | 19,226Stock Option (right to buy) | — | ↗ |
| Jun 3, 2026 | Schenkein David P | director | Acquired · Grant / award | 6,408 | — | ↗ |
| Jun 3, 2026 | Schenkein David P | director | Acquired · Grant / award | 19,226Stock Option (right to buy) | — | ↗ |
| Jun 3, 2026 | Klein Peter S | director | Acquired · Grant / award | 6,408 | — | ↗ |
| Jun 3, 2026 | Klein Peter S | director | Acquired · Grant / award | 19,226Stock Option (right to buy) | — | ↗ |
| Jun 3, 2026 | BAKER BROS. ADVISORS LP | director | Acquired · Grant / award | 6,408 | — | ↗ |
| Jun 3, 2026 | BAKER BROS. ADVISORS LP | director | Acquired · Grant / award | 6,408 | — | ↗ |
* Holdings as reported for Jun 30, 2026, 140 days old; funds file up to 45 days after each quarter-end, so the newest complete quarter runs 45 to 135 days behind.
** A price of “—” marks an option exercise, RSU vest or a filing without a usable per-share price, not a $0 trade.
Common questions
How much of Denali Therapeutics do institutions hold?
13F filers reported holding 98.2% of Denali Therapeutics' shares as of Jun 30, 2026, across 298 filers.
How many 13F filers hold Denali Therapeutics?
Denali Therapeutics was held by 298 13F filers as of Jun 30, 2026.
Not investment advice.

